Key result
2-Azidoadenosine inhibits platelet aggregation more than adenosine, while 2-azido-ADP is ~5x more potent than ADP.
Photolysable 2-azido analogues of adenosine, AMP, and ADP are potent modulators of human platelet aggregation and can be used to label their respective receptors.
Answers are grounded in this paper and cite their sources.
These analogues may enable platelet receptor labeling studies; clinical translation in humans remains untested.
The aggregating effect of ADP on human platelets and the inhibiting effect of adenosine are apparently mediated by different receptors on the cells’ outer membranes. Photolysable azido-analogues of adenosine, AMP and ADP have been prepared so that the receptors for them can be labelled. 2-Azidoadenosine inhibited platelet aggregation by ADP more than adenosine itself and increased platelet cAMP as effectively as did adenosine or 2-chloroadenosine. 2-Azido-AMP inhibited aggregation much more effectively than AMP itself or than 2-chloro-AMP. 2-Azido-ADP was about five times more potent than ADP in causing aggregation. All these 2-azido derivatives were photolysable by irradiation at 365 nm which does not affect platelet functions.
No takes yet. Share an insight, caveat, or question.
Cusack et al. (1977) studied this question. Photolysable 2-azido analogues of adenosine, AMP and ADP vs. Adenosine, AMP, and ADP was evaluated on Platelet aggregation and cAMP levels. 2-Azidoadenosine inhibited platelet aggregation more than adenosine, while 2-azido-ADP was about five times more potent than ADP in causing aggregation.
Synapse has enriched 10 related papers. Consider them for comparative context: